Quest Diagnostics recently announced the nationwide availability of the RestoreU Dementia Panel, an artificial intelligence (AI)-based risk assessment and care service created by uMETHOD Health. In this video interview, Dr. Michael K. Racke, medical director for neurology at Quest Diagnostics, spoke to Stephen Wellman, director of content and strategy at LabPulse and The Science Advisory Board, about the challenges associated with identifying those who do not have Alzheimer's and may…READ MORE

Quest Diagnostics unveiled a new artificial intelligence-based test service in the U.S. that aims to help physicians improve the detection of dementia and create better outcomes for patients. Through a partnership with Raleigh, N.C.-based health technology company uMETHOD Health, the Secaucus-headquartered testing provider added the RestoreU Dementia Panel to its testing portfolio, according to a May 4 announcement. Dr. Michael Racke, Quest’s neurology medical director, said, “With so much attention on emerging therapies for…READ MORE

More than six million Americans are living with Alzheimer’s disease — and one in three seniors dies with the disease, according to statistics from the Alzheimer’s Association. With so many different factors — genetics, lifestyle and environment — influencing a person’s risk of developing Alzheimer’s, many doctors are moving away from one-size-fits-all approaches and calling for more individualized treatments. It’s a concept known as precision medicine. And it’s what inspired a…READ MORE

Secaucus, NJ and Raleigh, NC – May 4, 2023 – Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced nationwide availability of the RestoreU™ Dementia Panel, a risk assessment and care plan service created by uMETHOD Health, a health technology company specializing in precision medicine for chronic diseases, to help physicians close care gaps for patients with cognitive decline. The RestoreU service employs artificial intelligence…READ MORE

Quest Diagnostics and uMETHOD Health, Inc. are excited to announce the national launch of a robust solution in the fight against dementia. Using a 3-step approach that combines our advanced testing with uMETHOD’s AI-based technology, you can help patients prevent cognitive decline, improve brain health, and maintain independence. Learn more about Quest Diagnostic's Alzheimer's disease testing portfolio at Questforthecure.com or contact a uMETHOD Health representative today.…READ MORE

Frontotemporal Dementia (FTD) is a neurodegenerative disease that affects two brain structures:  the frontal lobes and the temporal lobes. The location of damage is distinct from that of Alzheimer’s Disease (AD), which is characterized by the degeneration of the brain structure known as the hippocampus. For each of these conditions, neurodegeneration can be readily quantified by the amount of shrinkage (loss of tissue) in these structures, which can be observed…READ MORE

In February 2022, Dr. Federico Canavosio of Integrative Medical Care (IMC) in Vero Beach, FL started applying a new approach to memory care for patients aged 60 and older. IMC began working with medical AI company uMETHOD Health to deploy RestoreU, an evidence-based care program for patients at risk of developing Alzheimer’s Disease (AD), dementia, or other cognitive issues. “Cognitive impairment and related dementias are difficult to treat because they…READ MORE

Despite our annual expressions of gratitude to our veterans for all they’ve sacrificed, we fall short when it comes to their health and well-being. In addition to cancer, diabetes, and mental-health disorders, veterans suffer from Alzheimer’s Disease (AD) and other forms of dementia at high rates. Veterans currently under a physician’s care need a comprehensive workup and a care plan that addresses the factors that drive the progression of AD.…READ MORE

uMETHOD is excited to announce the release of its breakthrough methodology -- called ExtND METHOD -- designed to finally provide a prevention solution to the over 70 million women and men in the USA at risk of Alzheimer’s disease and cognitive decline. The complexity of treating and preventing cognitive decline due to dozens of biological mechanisms and hundreds of interventions is now made straightforward through the application of uMETHOD’s proprietary…READ MORE

At the 2019 Alzheimer’s Association International Conference, July 14-18, in Los Angeles, California, uMETHOD Health shared results from an analysis that evaluated the implementation of a precision-medicine platform to create personalized, multidomain care plans for the treatment of dementia and mild Alzheimer disease. The algorithms analyze medication interactions and adverse drug reactions, such as drug-drug interactions, opioid usage, anticholinergic cognitive burden, and depression-inducing drugs, rate them using input from an open-source…READ MORE